1 day Ago By Defense World Staff
Bank of New York Mellon Corp boosted its stake in shares of Castle Biosciences, Inc. ( NASDAQ:CSTL – Free Report ) by 15.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The firm owned 96,688 shares of the company’s stock after purchasing an additional 12,583 shares during the quarter. Bank of New York Mellon Corp owned about 0.35% of Castle Biosciences worth $2,105,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of CSTL. Summit Global Investments bought a new stake in Castle Biosciences in the 2nd quarter valued at about $518,000. SG Americas Securities LLC bought a new position in Castle Biosciences during the 2nd quarter worth $588,000.
Harbor Capital Advisors Inc. raised its holdings in Castle Biosciences by 249.3% in the 2nd quarter.
Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock valued at $3,020,000 after acquiring an additional 99,001 shares in the last quarter. Price T Rowe Associates Inc.
MD grew its holdings in shares of Castle Biosciences by 6.7% during the 1st quarter. Price T Rowe Associates Inc.
MD now owns 18,034 shares of the company’s stock worth $400,000 after purchasing an additional 1,131 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Castle Biosciences by 130.7% in the first quarter.
Acadian Asset Management LLC now owns 210,824 shares of the company’s stock worth $4,669,000 after purchasing an additional 119,443 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling In other news, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $22.
06, for a total transaction of $61,613.58. Following the completion of the transaction, the chief operating officer now owns 145,825 shares of the company’s stock, valued at $3,216,899.
50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . In related news, COO Kristen M.
Oelschlager sold 2,793 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $22.06, for a total transaction of $61,613.
58. Following the transaction, the chief operating officer now directly owns 145,825 shares in the company, valued at approximately $3,216,899.50.
The transaction was disclosed in a filing with the SEC, which is available through this hyperlink . Also, COO Kristen M. Oelschlager sold 12,989 shares of the stock in a transaction on Thursday, August 1st.
The shares were sold at an average price of $23.06, for a total transaction of $299,526.34.
Following the sale, the chief operating officer now directly owns 132,836 shares of the company’s stock, valued at approximately $3,063,198.16. The disclosure for this sale can be found here .
Over the last quarter, insiders have sold 33,665 shares of company stock worth $828,222. Corporate insiders own 7.20% of the company’s stock.
Analysts Set New Price Targets Get Our Latest Research Report on Castle Biosciences Castle Biosciences Stock Up 1.0 % Castle Biosciences stock opened at $31.25 on Wednesday.
Castle Biosciences, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $32.
53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.
92 and a current ratio of 8.12. The firm’s 50-day simple moving average is $25.
54 and its 200 day simple moving average is $23.09. The stock has a market cap of $862.
72 million, a PE ratio of -27.17 and a beta of 1.02.
Castle Biosciences ( NASDAQ:CSTL – Get Free Report ) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.
16) by $0.47. Castle Biosciences had a negative net margin of 1.
08% and a negative return on equity of 0.77%. The business had revenue of $87.
00 million for the quarter, compared to analyst estimates of $69.95 million. During the same quarter in the previous year, the firm posted ($0.
70) earnings per share. Research analysts predict that Castle Biosciences, Inc. will post -0.
58 EPS for the current fiscal year. Castle Biosciences Company Profile ( Free Report ) Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading Five stocks we like better than Castle Biosciences There Are Different Types of Stock To Invest In Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Unveiling The Power Of VWAP: A Key Indicator For Traders Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge 3 Best Fintech Stocks for a Portfolio Boost Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. ( NASDAQ:CSTL – Free Report ).
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
